The addition of docetaxel to androgen-deprivation therapy provides no benefit for patients with non-castrate disease.
Although androgen-deprivation therapy (ADT) remains the standard of care in metastatic prostate cancer, essentially all patients ultimately develop castration resistance and disease progression. Docetaxel (with prednisone) was FDA approved in 2004 for patients with castration-resistant disease after phase III trials demonstrated improvements in both overall survival and disease-related symptoms (e.g., N Engl J Med 2004; 351:1502). However, the optimal timing of docetaxel administration is undefined.
